{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-060085","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2025-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.565787+00:00","generated_at":"2026-05-23T03:58:38.405286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BridgeBio Q1: $36.7M Attruby revenue, net loss $167.4M, pipeline advances","bullets":["First full quarter of Attruby net product revenue $36.7M; 2,072 prescriptions from 756 prescribers since Nov 2024 FDA approval.","Net loss attributable to common stockholders $167.4M ($0.88 EPS) vs $35.2M ($0.20) YoY; total revenue $116.6M vs $211.1M.","Cash $540.6M at March 31, 2025; expects $105M milestone payments in Q2 for ex-U.S. BEYONTTRA approvals.","Phase 2 encaleret in hypoparathyroidism: 78% of 9 patients achieved normal blood & urine calcium within 5 days.","Priced $500M 1.75% convertible notes due 2031; used $459M to repay term loan; Thomas Trimarchi appointed President/CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-060085","json":"https://secwatch.observer/filing/0000950170-25-060085.json","markdown":"https://secwatch.observer/filing/0000950170-25-060085.md","text":"https://secwatch.observer/filing/0000950170-25-060085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/0000950170-25-060085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025060085/bbio-20250429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T03:58:38.405286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}